Insys utilizes proprietary technologies to develop product candidates that address the clinical shortcomings of existing commercial products.
Insys CEO Michael Babich said this is a tremendous achievement for the company, and evidences their continued dedication to the development of improved products in the supportive care and oncology space.
"We are excited for the prospects of Fentanyl SL Spray’s unique delivery system and look forward to building a sales force to launch this product candidate, if approved," Babich said.